Abatacept
-
Subject Areas on Research
- A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression.
- A pilot trial targeting the ICOS-ICOS-L pathway in nonhuman primate kidney transplantation.
- Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates.
- Anti-Leukocyte Function-Associated Antigen 1 Therapy in a Nonhuman Primate Renal Transplant Model of Costimulation Blockade-Resistant Rejection.
- Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.
- Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
- Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy.
- Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion.
- Belatacept: is there BENEFIT for liver transplantation too?
- CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model.
- CD57(+) CD4 T Cells Underlie Belatacept-Resistant Allograft Rejection.
- CTLA-4-Mediated inhibition of early events of T cell proliferation.
- CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.
- CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8.
- CTLA4Ig: bridging the basic immunology with clinical application.
- Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection.
- Costimulator dependence of lymphokine secretion by naive and activated CD4+ T lymphocytes from TCR transgenic mice.
- Costimulatory molecules are active in the human xenoreactive T-cell response but not in natural killer-mediated cytotoxicity.
- Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28.
- High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept.
- IFN-gamma dictates allograft fate via opposing effects on the graft and on recipient CD8 T cell responses.
- Immune status assay (ISA): a noninvasive procedure for studying allograft rejection.
- In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial.
- Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand.
- Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.
- LFA-1 blockade induces effector and regulatory T-cell enrichment in lymph nodes and synergizes with CTLA-4Ig to inhibit effector function.
- Molecular basis of T cell inactivation by CTLA-4.
- Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.
- Rapamycin Interferes With Postdepletion Regulatory T Cell Homeostasis and Enhances DSA Formation Corrected by CTLA4-Ig.
- Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.
- Role of interleukin 12 and costimulators in T cell anergy in vivo.
- Selective Targeting of High-Affinity LFA-1 Does Not Augment Costimulation Blockade in a Nonhuman Primate Renal Transplantation Model.
- Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis.
- Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression.
- Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials.
- Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study.
- Tacrolimus to Belatacept Conversion Following Hand Transplantation: A Case Report.
- The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation.
- Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis.